Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669023 | 0.86 | KMT2A (0.51) | KMT2AGCKAKR1C3PTGS2AKR1C2 | |
| SCHEMBL2646494 | 0.85 | AKR1C3 (0.57) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2646492 | 0.85 | AKR1C3 (0.57) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2646211 | 0.83 | AKR1C3 (0.56) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2645359 | 0.83 | AKR1C3 (0.56) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2645355 | 0.83 | AKR1C3 (0.56) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2646214 | 0.83 | AKR1C3 (0.56) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2646019 | 0.83 | AKR1C3 (0.56) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2646015 | 0.83 | AKR1C3 (0.56) | KMT2AAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL1107285 | 0.80 | GCK (0.49) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | KMT2A 2344/4885GCK 2/4885AKR1C3 1240/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | KMT2A 2260/4885GCK 2/4885AKR1C3 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.